IL-10-modulated human dendritic cells for clinical use: Identification of a stable and migratory subset with improved tolerogenic activity

Journal of Immunology

Volumn 197, Issue 9, 2016, Pages 3607-3617

  Kryczanowsky, Fanny ^a   Raker, Verena ^a   Graulich, Edith ^a   Domogalla, Matthias P ^a   Steinbrink, Kerstin ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; SECONDARY LYMPHOID TISSUE CHEMOKINE; CCR7 PROTEIN, HUMAN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; IL10 PROTEIN, HUMAN; IMMUNOGLOBULIN; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD83HIGH CCR7+ IL 10 DENDRITIC CELL; CD83LOW CCR7- IL 10 DENDRITIC CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INFLAMMATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; TRANSPLANTATION;

ANTIGENS, CD; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL21; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULINS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, CCR7; T-LYMPHOCYTES, REGULATORY;

EID: 84992388765     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501769     Document Type: Article

References (38)

1. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
2. Hubo, M., B. Trinschek, F. Kryczanowsky, A. Tuettenberg, K. Steinbrink, and H. Jonuleit. 2013. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front. Immunol. 4: 82.
3. (H)2 and tolerogenic responses. Nat. Immunol. 11: 647-655.
4. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
5. Palucka, K., and J. Banchereau. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38-48.
6. Dhodapkar, M. V., and R. M. Steinman. 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 100: 174-177.
7. Dhodapkar, M. V., R. M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193: 233-238.
8. Piemonti, L., P. Monti, P. Allavena, M. Sironi, L. Soldini, B. E. Leone, C. Socci, and V. Di Carlo. 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 162: 6473-6481.
9. Naranjo-Gómez, M., D. Räich-Regué, C. Oñate, L. Grau-López, C. Ramo-Tello, R. Pujol-Borrell, E. Martínez-Cáceres, and F. E. Borràs. 2011. Comparative study of clinical grade human tolerogenic dendritic cells. J. Transl. Med. 9: 89.
10. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178: 7018-7031.
11. Boks, M. A., J. R. Kager-Groenland, M. S. Haasjes, J. J. Zwaginga, S. M. van Ham, and A. ten Brinke. 2012. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-a comparative study of human clinical-applicable DC. Clin. Immunol. 142: 332-342.
12. + T cells. J. Immunol. 184: 1765-1775.
13. 3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 164: 4443-4451.
14. Steinbrink, K., M. Wölfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-4780.
15. Steinbrink, K., H. Jonuleit, G. Müller, G. Schuler, J. Knop, and A. H. Enk. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93: 1634-1642.
16. Steinbrink, K., E. Graulich, S. Kubsch, J. Knop, and A. H. Enk. 2002. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99: 2468-2476.
17. Gregori, S., D. Tomasoni, V. Pacciani, M. Scirpoli, M. Battaglia, C. F. Magnani, E. Hauben, and M. G. Roncarolo. 2010. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116: 935-944.
18. Enk, A. H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73: 309-316.
19. Saito, M., M. Nagasawa, H. Takada, T. Hara, S. Tsuchiya, K. Agematsu, M. Yamada, N. Kawamura, T. Ariga, I. Tsuge, et al. 2011. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med. 208: 235-249.
20. Velten, F. W., K. Duperrier, J. Bohlender, P. Metharom, and S. Goerdt. 2004. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur. J. Immunol. 34: 2800-2811.
21. Prechtel, A. T., N. M. Turza, A. A. Theodoridis, and A. Steinkasserer. 2007. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J. Immunol. 178: 5454-5464.
22. Kruse, M., O. Rosorius, F. Krätzer, G. Stelz, C. Kuhnt, G. Schuler, J. Hauber, and A. Steinkasserer. 2000. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J. Virol. 74: 7127-7136.
23. Sánchez-Sánchez, N., L. Riol-Blanco, and J. L. Rodríguez-Fernández. 2006. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176: 5153-5159.
24. Worbs, T., and R. Förster. 2007. A key role for CCR7 in establishing central and peripheral tolerance. Trends Immunol. 28: 274-280.
25. Förster, R., A. C. Davalos-Misslitz, and A. Rot. 2008. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 8: 362-371.
26. Roncarolo, M. G., and S. Gregori. 2008. Is FOXP3 a bona fide marker for human regulatory T cells? Eur. J. Immunol. 38: 925-927.
27. Johnson, L. A., and D. G. Jackson. 2013. Control of dendritic cell trafficking in lymphatics by chemokines. Angiogenesis 17: 335-45.
28. high human monocyte-derived dendritic cells. Mol. Immunol. 44: 1544-1550.
29. Wuest, S. C., J. H. Edwan, J. F. Martin, S. Han, J. S. Perry, C. M. Cartagena, E. Matsuura, D. Maric, T. A. Waldmann, and B. Bielekova. 2011. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17: 604-609.
30. + T cells. J. Leukoc. Biol. 84: 460-467.
31. Binder, M., F. N. Vögtle, S. Michelfelder, F. Müller, G. Illerhaus, S. Sundararajan, R. Mertelsmann, and M. Trepel. 2007. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 67: 3518-3523.
32. Du, J., H. Yang, D. Zhang, J. Wang, H. Guo, B. Peng, Y. Guo, and J. Ding. 2010. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J. Immunol. 184: 1361-1368.
33. Gordon, J. R., Y. Ma, L. Churchman, S. A. Gordon, and W. Dawicki. 2014. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front. Immunol. 5: 7.
34. Giannoukakis, N., B. Phillips, D. Finegold, J. Harnaha, and M. Trucco. 2011. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34: 2026-2032.
35. Hilkens, C. M., and J. D. Isaacs. 2013. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin. Exp. Immunol. 172: 148-157.
36. Amodio, G., and S. Gregori. 2012. Human tolerogenic DC-10: perspectives for clinical applications. Transplant. Res. 1: 14.
37. Pacciani, V., S. Gregori, L. Chini, S. Corrente, M. Chianca, V. Moschese, P. Rossi, M. G. Roncarolo, and F. Angelini. 2010. Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. J. Allergy Clin. Immunol. 125: 727-736.
38. von Bergwelt-Baildon, M. S., A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al. 2006. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237.